Categories
CDE Diabetes

Practice Exam: Cardiovascular Protection in People with Diabetes (Chapter 23)

Cardiovascular disease (CVD) remains the leading cause of death for people living with diabetes. The 2018 Clinical Practice Guidelines emphasize that diabetes significantly accelerates the natural history of CVD, making aggressive risk reduction a cornerstone of management.

This practice exam tests your ability to implement the comprehensive “ABCDEs” of cardiovascular protection, ranging from lifestyle interventions to the use of cardioprotective pharmacotherapy.

Key Concepts Covered in This Exam:

  • Risk Assessment: Differentiating between proximate (<10 years) and lifetime risk, especially in younger patients who may have low short-term risk but high relative risk.

  • Lipid Management: Identifying the indications for statin therapy and the specific targets for Low-Density Lipoprotein Cholesterol (LDL-C).

  • Blood Pressure Control: Applying the correct targets and selecting preferred pharmacological agents (e.g., ACE inhibitors or ARBs) for renal and cardiovascular protection.

  • Cardioprotective Agents: Recognizing the specific roles of SGLT2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular events independent of glycemic control.

  • Antiplatelet Therapy: Understanding when aspirin therapy is indicated for secondary prevention versus the nuances of primary prevention.

1. A meta-analysis compared the CV safety of sulfonylureas with active comparators in people with type 2 diabetes. What did the meta-analysis of 115 trials find regarding sulfonylureas?

2. A 35-year-old man with type 1 diabetes of 18 years duration has microalbuminuria but no clinical CVD. He asks about statin therapy. According to the guidelines, should he receive statin therapy?

3. Which observation from the ADVANCE trial has been linked to future CV events, microvascular events, and all-cause mortality?

4. Diabetes confers a cardiovascular disease (CVD) event risk equivalent to aging approximately how many years?

5. A clinician is considering the evidence regarding ACE inhibitors for CV protection in diabetes. In the meta-analysis of ACE inhibitors

6. Why do pooled estimates suggest that ASA should not be used routinely for primary CVD prevention in people with diabetes?

7. A 52-year-old woman with type 2 diabetes currently smokes 1 pack per day. She has no other CV risk factors. How does smoking affect CV risk in people with diabetes?

8. What was the relative risk reduction in major adverse cardiac events (MACE) in the STENO-2 trial after 13 years of follow-up?

9. What is the recommended blood pressure target for people with diabetes according to the guidelines?

10. What A1C target is generally recommended as part of the comprehensive CV risk reduction approach?

11. Which diabetes complication is described as an emerging recognition of a nonatherothrombotic cause of morbidity and mortality?

12. According to the guidelines, at what age should people with diabetes and an additional CV risk factor or end organ damage be considered for ACE inhibitor or ARB therapy for vascular protection?

13. A 60-year-old man with type 2 diabetes and established CVD is allergic to ASA. He needs antiplatelet therapy for secondary prevention. What alternative antiplatelet agent can be used?

14. The ACCORD trial examined intensive glycemic control (A1C 6.4-6.9%) vs. standard control in people with established type 2 diabetes and CVD or multiple CV risk factors. What was the concerning finding that led to early termination of the ACCORD trial?

15. In the EMPA-REG OUTCOME trial, what was the primary driver of CVD risk reduction with empagliflozin?

16. What is the key point regarding the elimination of the 2013 guideline recommendation to start ACE inhibitor or ARB in all people with diabetes ≥55 years without CV risk factors or end organ damage?

17. A 62-year-old woman with type 2 diabetes and a history of myocardial infarction is not achieving glycemic targets on metformin. Her eGFR is 45 mL/min/1.73 m². Which class of antihyperglycemic agent should be considered to reduce her CV risk?

18. What does “vascular age” refer to in the context of CVD risk assessment?

19. In the Nurses’ Health Study, women with type 2 diabetes who performed at least 4 hours per week of moderate or vigorous exercise had what percent lower risk of developing CVD?

20. A 50-year-old woman with type 2 diabetes and no history of CVD asks whether she should take ASA daily for heart attack prevention. What is the guideline recommendation regarding ASA for primary prevention of CVD in diabetes?

21. A 45-year-old man with type 2 diabetes and clinical CVD is on statin therapy but his LDL-C remains significantly elevated. He has familial hypercholesterolemia. Which class of medication may be considered for this patient to further reduce MACE?

22. A 55-year-old man with type 2 diabetes has no history of cardiovascular disease and an LDL-C=1.8 mmol/L.  He asks about starting statin therapy. According to the guidelines, should this patient receive statin therapy?

23. In the CANVAS study with canagliflozin, what safety concerns were identified?

24. A 58-year-old man with type 2 diabetes and established coronary artery disease is on a statin but has not reached his LDL-C target of <1.8 mmol/L. What second-line agent should generally be considered to help achieve LDL-C goals?

25. What is the eGFR threshold below which SGLT2 inhibitors with demonstrated CV outcome benefit are not recommended according to these guidelines?

26. In the STENO-2 trial, what was the number needed to treat (NNT) for mortality reduction?

27. At what age does diabetes transition from intermediate to high CVD risk in men?

28. For secondary prevention of CVD events in people with diabetes, what dose of ASA is recommended?

29. In the ABCDES framework for cardiovascular risk reduction, what does the “C” represent?


 

Categories
CDE Diabetes

Study Guide: Cardiovascular Protection in People with Diabetes (Chapter 23)

1. Overview & Pathophysiology

Cardiovascular disease (CVD) is the primary cause of death for people with diabetes.

  • Vascular Age: Diabetes significantly accelerates vascular aging. Having diabetes confers a CVD risk equivalent to aging approximately 15 years.
  • Proximate vs. Lifetime Risk: While young people with diabetes may have low proximate (<10 years) risk, their lifetime risk is extremely high. Therefore, early intervention is justified.

  • The “Vascular Protection” Concept: Multifactorial intervention (treating lipids, BP, glucose, and lifestyle simultaneously) provides benefit greater than the sum of its parts.

    • Key Study: The STENO-2 Trial showed that intensive multifactorial intervention reduced major adverse cardiac events (MACE) by 53% and mortality by 20%.

 

2. Patient Education: The ABCDEs

The guidelines recommend teaching patients the “ABCDEs” to reduce heart attack and stroke risk :

  • A = A1C (Target usually ).

  • B = BP (Target mmHg).

  • C = Cholesterol (LDL-C mmol/L).

  • D = Drugs to protect the heart (ACEi/ARBs, Statins, and specific glucose-lowering agents like SGLT2i/GLP-1 RA).

  • E = Exercise / Eating (Healthy behaviors).

  • S = Stop Smoking (and manage Stress)

3. Pharmacotherapy for CV Protection

This section focuses on the “D” (Drugs) of the ABCDEs.

A. Lipid-Modifying Therapies (Statins)

Statins are recommended based on risk categories, not just LDL levels.

  • Who needs a Statin?
    1. Clinical CVD: Anyone with established cardiovascular disease.
    2. Age 40 years: All individuals with Type 2 diabetes.
    3. Age < 40 years: Only if “High Risk,” defined as:
      • Diabetes duration years (and age ).
      • Microvascular complications present.
      • Warrants therapy based on other risk factors (e.g., Familial Hypercholesterolemia).
  • Second-Line: If LDL goals are not met, Ezetimibe or PCSK-9 inhibitors (Evolocumab) may be added.

B. RAAS Inhibition (ACE Inhibitors / ARBs)

  • Indication:
    • Clinical CVD: All patients.
    • Age 55 years: If they have one additional CV risk factor OR end-organ damage (albuminuria, retinopathy, LVH).
    • Microvascular Complications: To delay progression (e.g., albuminuria).
  • Note: The previous recommendation to treat everyone regardless of risk factors was removed in 2018. Now requires an additional risk factor or end-organ damage.
  • Pregnancy: ACEi/ARBs and Statins are contraindicated in pregnancy.

C. Antiplatelet Therapy (ASA / Aspirin)

  • Secondary Prevention: YES. Routine use (81–162 mg) is recommended for those with established CVD.
  • Primary Prevention: NO. ASA should not be used routinely for primary prevention due to bleeding risks outweighing benefits.
    • Exception: May be considered on an individual basis for those with very high risk/multiple risk factors.
  • Clopidogrel: Use if ASA intolerant.

D. Antihyperglycemic Agents with CV Benefit

For patients with Type 2 diabetes and clinical CVD who are not at glycemic target, specific agents with proven CV benefit should be prioritized:

  • Empagliflozin (SGLT2i): Reduced CV mortality and all-cause mortality (EMPA-REG OUTCOME).

  • Liraglutide (GLP-1 RA): Reduced MACE (CV death, non-fatal MI, stroke) (LEADER).

  • Canagliflozin (SGLT2i): Reduced MACE (CANVAS), but noted increased amputation risk in trial.

(NOTE: Since the publication of the guidelines semaglutide po/sc and tirzepatide have demonstrated significant effect on MACE)

4. Glycemic Control & CV Outcomes (The Trials)

Understanding the difference between early and late intervention is key.

  • Early Intervention (DCCT/UKPDS): Intensive control early in the disease course has a “legacy effect,” reducing CV events long-term.
  • Late Intervention (ACCORD/ADVANCE/VADT): In older patients with long-standing diabetes and CVD risk, intensive glucose lowering (targeting A1C < 6.0-6.5%) did NOT reduce CV events and increased mortality in the ACCORD trial.
    • Takeaway: Aggressive A1C targets may be dangerous in high-risk, long-standing diabetes.

5. Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S169).

  1. Statin Therapy: Recommended for all with clinical CVD, or Type 2 diabetes Age 40, or young patients with microvascular complications/long duration [Grade A/D].
  2. ACEi/ARB: Recommended for clinical CVD, or Age 55 with add-on risk/organ damage, or microvascular complications [Grade A/D].
  3. ASA: Recommended for Secondary Prevention [Grade B]. Not recommended routinely for Primary Prevention [Grade A].
  4. CVD Benefit Agents: In adults with T2D and clinical CVD, add Empagliflozin [Grade A, Level 1A], Liraglutide [Grade A, Level 1A], or Canagliflozin [Grade C, Level 2] if not at target.

Reference:

Stone JA, Houlden RL, Lin P, Udell JA, Verma S. Cardiovascular Protection in People With Diabetes. Canadian Journal of Diabetes. 2018;42:S162-S169. doi:10.1016/j.jcjd.2017.10.024
Categories
CDE Diabetes

Flashcards: Complementary and Alternative Medicine for Diabetes (Chapter 22)

With nearly half of all people with diabetes reporting the use of complementary or alternative medicine (CAM), it is crucial for healthcare professionals to separate evidence-based potential from proven inefficacy or harm. These flashcards are designed to help you quickly recall the 2018 Clinical Practice Guidelines regarding the efficacy, safety, and drug interactions of various natural health products (NHPs) and alternative modalities.

Key Topics Covered:

  • Efficacy Evidence: Distinguishing between NHPs with potential benefits (e.g., fenugreek, flaxseed) and those that have consistently failed to show benefit in large trials (e.g., cinnamon, chromium, vitamin D)

  • Safety & Regulation: Understanding the risks of contamination and the importance of recommending only products with a Natural Product Number (NPN).

  • Drug-Herb Interactions: Identifying critical interactions, such as St. John’s Wort inducing CYP3A4 and reducing the efficacy of statins and other medications.

  • Adverse Effects: Recalling specific risks, such as the abortifacient properties of bitter melon or the hypoglycemic risk of products adulterated with glyburide.

  • Mind-Body Therapies: Reviewing the evidence for yoga and other modalities in improving glycemic control and cardiovascular risk factors .

Categories
CDE Diabetes

Practice Exam: Complementary and Alternative Medicine for Diabetes (Chapter 22)

With 25% to 57% of people with diabetes reporting the use of complementary or alternative medicine, it is essential for healthcare professionals to understand the current evidence base. While many patients seek these therapies to align with their values or due to dissatisfaction with conventional care, the evidence for efficacy and safety varies significantly.

This practice exam tests your knowledge of the 2018 Clinical Practice Guidelines regarding Natural Health Products (NHPs), mind-body practices, and the critical importance of identifying potential drug-herb interactions.

Key Concepts Covered in This Exam:

  • Prevalence & Disclosure: Recognizing the high rate of CAM usage and the recommendation that healthcare providers must actively ask patients about their use of these therapies.
  • Evidence of Efficacy: Identifying which NHPs have shown potential A1C reduction (0.5%) in small trials (e.g., fenugreek, flaxseed) versus those that have failed to show consistent benefit in larger trials (e.g., cinnamon, chromium, vitamin D).
  • Safety & Regulation: Understanding the risks of adulteration and the importance of using products with a Natural Product Number (NPN), as well as specific risks like hepatotoxicity or hypoglycemia.
  • Drug Interactions: Knowing well-documented interactions, such as the effect of St. John’s Wort on cytochrome P450 3A4 (CYP3A4) and its impact on statins and other medications.
  • Mind-Body Modalities: Reviewing the evidence for non-pharmacologic approaches like yoga, which may offer benefits for glycemic control and lipid profiles.

Please go to Practice Exam: Complementary and Alternative Medicine for Diabetes (Chapter 22) to view this quiz

Categories
CDE Diabetes

Study Guide: Complementary and Alternative Medicine (Chapter 22)

1. Overview & Definitions

Usage of Complementary and Alternative Medicine (CAM) is high among people with diabetes (estimates range from 25% to 57%).

  • Complementary: Used together with conventional medicine.

  • Alternative: Used in place of conventional medicine.

  • Natural Health Products (NHP): Include vitamins, minerals, herbal remedies, and traditional medicines. In Canada, these are regulated and have a Natural Product Number (NPN), but evidence quality is generally lower than for pharmaceuticals.

2. Efficacy of Natural Health Products (NHPs)

The guidelines categorize NHPs based on their ability to lower A1C in randomized controlled trials (RCTs).

A. Products showing potential A1C reduction ( 0.5%) These have shown promise in small trials, but evidence is insufficient to recommend them for widespread use.

  • Glycemic Control: Aloe vera (oral), Berberine, Fenugreek (Trigonella foenum-graecum), Ginger, Magnesium, Silymarin (Milk Thistle), Flaxseed oil (high dose).
  • Note on Berberine: Meta-analysis shows it may reduce triglycerides and increase HDL more than traditional drugs, and lower BP when used as an adjunct.

B. Products with No Benefit or Conflicting Evidence Despite popular belief, these have generally failed to consistently show benefit for glycemic control in robust studies.

  • Cinnamon: Conflicting results; some studies show benefit, others do not.
  • Chromium: Meta-analyses show no benefit on A1C, lipids, or weight, despite early theories about deficiency causing insulin resistance.
  • Vitamin D: While important for bone health, supplementation does not improve glycemic control (A1C) in people with diabetes.
  • Others with lack of benefit: Vitamin C, Vitamin E, Ginseng (variable/heterogeneous), Green Tea (Camellia sinensis).

3. Safety Concerns & Interactions (High Yield for CDE Exam)

CDEs must be vigilant about “natural” products having pharmacological effects or contaminants.

  • Xiaoke Pills: A Traditional Chinese Medicine (TCM) that often contains glibenclamide (glyburide). Patients taking this may be at risk of severe hypoglycemia, especially if taking other sulfonylureas.
  • St. John’s Wort (Hypericum perforatum): Induces Cytochrome P450 3A4 (CYP3A4). It can reduce the effectiveness of many drugs, including statins and some antihypertensives.
  • Bitter Melon (Momordica charantia): Used for glucose lowering, but is an abortifacient and should be avoided in pregnancy.
  • Nettle: Has insulin secretagogue activity; potential additive hypoglycemia risk.

4. Other CAM Modalities

A. Mind-Body Practices

  • Xiaoke Pills: A Traditional Chinese Medicine (TCM) that often contains glibenclamide (glyburide). Patients taking this may be at risk of severe hypoglycemia, especially if taking other sulfonylureas.
  • St. John’s Wort (Hypericum perforatum): Induces Cytochrome P450 3A4 (CYP3A4). It can reduce the effectiveness of many drugs, including statins and some antihypertensives.
  • Bitter Melon (Momordica charantia): Used for glucose lowering, but is an abortifacient and should be avoided in pregnancy.
  • Nettle: Has insulin secretagogue activity; potential additive hypoglycemia risk.

4. Other CAM Modalities

A. Mind-Body Practices

  • Yoga: Regular practice (e.g., 3 times/week) may improve A1C, lipids, and blood pressure. Some data suggests it is more effective than walking or Tai Chi for lowering A1C.
  • Tai Chi: Little evidence for glycemic benefit, though may improve quality of life.

B. Physical Treatments

  • Acupuncture: No evidence for improving A1C. Some low-quality evidence suggests benefit for diabetic neuropathy symptoms or gastroparesis symptoms .
  • Chelation Therapy (EDTA): The TACT trial showed a reduction in cardiovascular events in patients with prior MI and diabetes.
  • Reflexology: Small studies suggest potential benefit for neuropathy pain and glycemic control.

5. Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S157).

  1. Ask the Question: Health-care providers should ask about the use of complementary and alternative medicine in people with diabetes [Grade D, Consensus].
  2. Insufficient Evidence: There is insufficient evidence to make a recommendation regarding the efficacy and safety of CAM for individuals with diabetes [Grade D, Consensus].
    • Interpretation: Do not actively recommend these products for diabetes management, but be prepared to discuss safety/interactions if patients use them.

 

Reference:

Grossman LD, Roscoe R, Shack AR. Complementary and Alternative Medicine for Diabetes. Canadian Journal of Diabetes. 2018;42:S154-S161. doi:10.1016/j.jcjd.2017.10.023
Categories
CDE Diabetes

Flashcards: Diabetes and Driving (Chapter 21)

Driving with diabetes requires careful management to ensure safety for the driver and the public. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding medical assessments, the “safe to drive” blood glucose thresholds, and the responsibilities of both patients and providers.

Key Topics Covered:

  • Assessment Intervals: Recalling that all drivers with diabetes need a medical exam every 2 years, while commercial drivers have stricter requirements [cite: Ch21-Diabetes-and-Driving.pdf].

  • The “40-Minute Rule”: Memorizing the protocol that if blood glucose is <4.0 mmol/L, driving must cease until treatment raises glucose to at least 5.0 mmol/L and 40 minutes have passed.

  • Hypoglycemia Unawareness: Identifying this as a major risk factor that may require more frequent testing (every 2 hours) or Continuous Glucose Monitoring (CGM) while driving.

  • Commercial vs. Private: Differentiating the reporting and assessment standards for commercial drivers, who face higher scrutiny due to increased road exposure.

  • Patient Duty: Understanding the patient’s obligation to report any severe hypoglycemic event to their healthcare team and licensing body.

Categories
CDE Diabetes

Practice Exam: Diabetes and Driving (Chapter 21)

Driving is a complex task that can be impacted by both the acute complications of diabetes (such as hypoglycemia) and chronic complications affecting vision or sensation. The 2018 Clinical Practice Guidelines emphasize that the fitness to drive must be assessed on an individual basis, balancing public safety with the quality of life for people with diabetes.

This practice exam tests your ability to apply the specific medical standards for private and commercial drivers, as well as your knowledge of the “safe driving” protocols that all insulin-treated drivers must follow.

Key Concepts Covered in This Exam:

  • Assessment Standards: Understanding that all drivers with diabetes should undergo a medical examination at least every 2 years, while commercial drivers require assessment at the time of license application.
  • Hypoglycemia Risks: Identifying unrecognized hypoglycemia as the most relevant driving hazard, with performance deteriorating at blood glucose levels below 3.8 mmol/L.
  • The “40-Minute Rule”: Mastering the safety protocol that if blood glucose is <4.0 mmol/L, the driver must not drive until at least 40 minutes after successful treatment to allow for cognitive recovery.
  • Patient Responsibilities: Recognizing the duty of the person with diabetes to report conditions like hypoglycemia unawareness or severe hypoglycemic episodes to their healthcare provider and licensing body.
  • Reporting Requirements: Differentiating between mandatory and discretionary reporting provinces and understanding the healthcare professional’s role in identifying high-risk drivers.

Please go to Practice Exam: Diabetes and Driving (Chapter 21) to view this quiz

Categories
CDE Diabetes

Study Guide: Diabetes and Driving (Chapter 21)

1. Overview & Rationale

Diabetes can affect driving safety primarily through the risk of hypoglycemia (which impairs cognitive and motor function) and long-term complications (like retinopathy or neuropathy) that affect sensory/motor abilities.

  • Individual Assessment: Fitness to drive must be assessed on an individual basis.

  • The Major Risk: Severe hypoglycemia is the most significant predictor of driving accidents among people with diabetes.

  • Shared Responsibility: Safety is a shared responsibility between the person with diabetes, the healthcare team, and the licensing bodies.

2. Medical Assessment for Fitness to Drive

The frequency and stringency of medical assessments depend on the type of license held.

FeaturePrivate
Drivers 		Commercial
Drivers
Assessment FrequencyAt least every 2 years (or more often if clinically indicated).At time of application and then as per provincial requirements.
Hypo RiskLower standard than commercial.Stricter standard.
ExclusionMay be restricted if uncontrolled severe hypoglycemia or unawareness.Often disqualified if they have severe hypoglycemia or hypoglycemia unawareness.

Key Assessment Components:

  1. Hypoglycemia History: Frequency, severity, and awareness of hypoglycemia in the past 12 months.

  2. Complications:

    • Vision: Retinopathy, cataracts, visual acuity, field of vision.

    • Neuropathy: Sensory or motor loss in limbs affecting pedal use.

    • Cognition: Impairment affecting judgment or reaction time.

3. High-Risk Drivers

Healthcare providers must identify individuals at increased risk of accidents.

Red Flags for Driving Safety:

  • Severe Hypoglycemia: Any episode of severe hypoglycemia (requiring assistance) in the past 12 months.

  • Hypoglycemia Unawareness: Inability to detect dropping glucose levels.

  • Recent instability: Unexplained or uncontrolled fluctuation in blood glucose.

  • Non-adherence: Failure to follow “safe driving” protocols (e.g., testing before driving).

4. Patient Education: The "Safe Driving" Protocol

Educating patients on how to drive safely is a mandatory CDE competency.

Before Driving:

  • Measure: Check blood glucose (BG) immediately before driving.

  • Safe Threshold:

    • If BG 4.0 mmol/L: Safe to drive (though some experts suggest 5.0 mmol/L is a safer buffer).

    • If BG < 4.0 mmol/L: DO NOT DRIVE. Treat with 15g carbs, retest in 15 mins.

    • Note: Even if BG is 4.0–5.0 mmol/L, consider a snack to prevent a drop during the drive.

While Driving (Long Trips):

  • Check BG every 4 hours during continuous driving.

  • Carry rapid-acting carbohydrates within easy reach (console, passenger seat).

If Hypoglycemia Occurs While Driving:

  1. Stop: Pull over safely immediately.

  2. Turn Off: Turn off the engine and remove keys (to legally establish you are not “driving”).

  3. Treat: Ingest 15g fast-acting carbohydrate.

  4. Wait: Wait 40 minutes after BG has returned to normal (> 4.0 mmol/L) before driving again.

    • Why 40 minutes? It takes time for cognitive recovery (brain function) to fully return even after the blood sugar is normal.

5. Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section.

  1. Individual Assessment: Fitness to drive should be assessed individually for all people with diabetes [Grade D, Consensus].

  2. Mandatory Exams:

    • Private Drivers: Medical examination at least every 2 years [Grade D, Consensus].

    • Commercial Drivers: Examination at application and as per provincial rules [Grade D, Consensus].

  3. Risk Factors: Assessing fitness to drive should include reviewing severe hypoglycemia episodes, hypoglycemia unawareness, and complications (retinopathy, neuropathy, nephropathy, CVD) [Grade D, Consensus].

  4. Patient Education: People with diabetes treated with insulin/secretagogues should be instructed to:

    • Keep fast-acting carbs within reach [Grade D, Consensus].

    • Measure BG before driving and every 4 hours during long drives [Grade D, Consensus].

    • Stop immediately if hypo occurs, treat, and wait 40 minutes after recovery before driving [Grade B, Level 2].

Reference:

Houlden RL, Berard L, Lakoff JM, Woo V, Yale JF. Diabetes and Driving. Canadian Journal of Diabetes. 2018;42:S150-S153. doi:10.1016/j.jcjd.2017.10.018
Categories
CDE Diabetes

Flashcards: Diabetes and Transplantation (Chapter 20)

Transplantation represents a life-changing therapeutic option for select patients with diabetes, particularly those with end-stage renal disease (ESRD). These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding the specific benefits of kidney, pancreas, and islet transplantation, as well as the management of post-transplant complications.

Key Topics Covered:

  • Kidney Transplantation: Understanding the evidence that kidney transplantation provides superior long-term survival compared to dialysis for patients with diabetes and ESRD.

  • Simultaneous Pancreas-Kidney (SPK): Identifying SPK as a strategy to prolong insulin independence and improve kidney graft survival in Type 1 diabetes.

  • Islet Transplantation: Recognizing the role of islet allotransplantation in preventing severe hypoglycemia, despite the trade-off of long-term immunosuppression.

  • Islet Autotransplantation: Recalling the indication for this procedure in patients undergoing total pancreatectomy for benign disease to prevent labile diabetes.

  • Post-Transplant Diabetes (PTDM): Managing the risks associated with PTDM, including its impact on graft loss, cardiovascular disease, and mortality.

Categories
CDE Diabetes

Practice Exam: Diabetes and Transplantation (Chapter 20)

For people with diabetes and end-stage renal disease (ESRD), transplantation offers the potential for significantly improved survival and quality of life compared to dialysis. However, the procedure introduces new challenges, including the management of post-transplant diabetes mellitus (PTDM) and the complex side effects of immunosuppressive therapy.

This practice exam tests your understanding of the indications for various transplant modalities (kidney, pancreas, islet) and the evidence-based strategies for managing glycemic control in the transplant recipient.

Key Concepts Covered in This Exam:

  • Renal Replacement: Understanding the evidence that kidney transplantation improves long-term outcomes compared to dialysis for individuals with diabetes and ESRD.

  • Transplant Types: Differentiating between Simultaneous Pancreas-Kidney (SPK) transplantation, which can prolong insulin independence, and islet allotransplantation, which focuses on preventing severe hypoglycemia.

  • Islet Autotransplantation: Recognizing the role of this procedure in preventing labile diabetes for patients undergoing total pancreatectomy for benign disease.

  • Post-Transplant Diabetes (PTDM): Identifying PTDM as a common complication after solid organ transplantation that increases the risk of graft loss, cardiovascular disease, and mortality.

  • Management Considerations: Balancing glycemic targets with the metabolic impact of antirejection medications.

Please go to Practice Exam: Diabetes and Transplantation (Chapter 20) to view this quiz